Ocular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data
<b>Background/Objectives:</b> Early stages of diabetic retinopathy are currently considered an unmet medical need due to the lack of effective treatments beyond proper monitoring and control of glycemia and blood pressure. Sitagliptin eye drops have emerged as a new therapeutic approach...
Saved in:
Main Authors: | Cristina Hernández, Hugo Ramos, Anne Létondor, Rafael Simó |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-11-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/17/12/1579 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2 +/− rat model
by: Hugo Ramos, et al.
Published: (2024-11-01) -
Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the Hospital Pharmacy Departments
by: Anxo Fernández-Ferreiro, et al.
Published: (2016-12-01) -
Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases
by: Neslihan USLU, et al.
Published: (2024-06-01) -
Galenic validation of plasma rich in growth factors eye drops
by: Eduardo Anitua, et al.
Published: (2019-03-01) -
Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
by: Juan Wang, et al.
Published: (2022-11-01)